Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mirna Therapeutics, a discovery-stage biopharmaceutical R&D company and a wholly owned subsidiary of Asuragen, and The University of Texas M D Anderson Cancer Center Science Park Research Center in Smithville, have entered into a collaboration to investigate microRNAs in human prostate cancer.
Subscribe to our email newsletter
The principal investigators for the study are Dean Tang, associate professor of division of carcinogenesis and adjunct associate professor of college of pharmacy at The University of Texas and David Brown, director of discovery from Mirna.
Matt Winkler, CEO of Mirna, said: “We are excited about the therapeutic collaboration with M D Anderson. Combining M D Anderson’s extensive knowledge of prostate cancer biology with Asuragen’s expertise using miRNA with therapeutic potential could lead to improved treatment options for prostate cancer.”